These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 4198296)

  • 1. Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity.
    Defelice EA; Chaykin LB; Cohen A
    Curr Ther Res Clin Exp; 1973 Jul; 15(7):358-66. PubMed ID: 4198296
    [No Abstract]   [Full Text] [Related]  

  • 2. Obesity-depression: clinical evaluation with a new anorexigenic agent.
    Kornhaber A
    Psychosomatics; 1973; 14(3):162-7. PubMed ID: 4604838
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 4. A double blind controlled trial of a new anorectic agent AN448.
    Woodhouse SP; Nye ER; Anderson K; Rawlings J
    N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new anorexiant. Clinical evaluation.
    Smith DE
    Rocky Mt Med J; 1974 Jan; 71(1):41-4. PubMed ID: 4131377
    [No Abstract]   [Full Text] [Related]  

  • 6. Controlled clinical evaluation of a new anorectic agent in obese adults.
    Elmaleh MK; Miller J
    Pa Med; 1974 Sep; 77(9):46-50. PubMed ID: 4609056
    [No Abstract]   [Full Text] [Related]  

  • 7. A double-blind evaluation of an anorexiant, a placebo and diet alone in obese subjects.
    Resnick M; Joubert L
    Can Med Assoc J; 1967 Oct; 97(17):1011-5. PubMed ID: 6052899
    [No Abstract]   [Full Text] [Related]  

  • 8. Double-blind comparison of placebo and 42-548, a new appetite suppressant, in obese volunteers.
    De Felice EA; Bronstein S; Cohen A
    Curr Ther Res Clin Exp; 1969 May; 11(5):256-62. PubMed ID: 4977396
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blind trial of anorectic agents.
    Sproule BC
    Med J Aust; 1969 Feb; 1(8):394-5. PubMed ID: 4889477
    [No Abstract]   [Full Text] [Related]  

  • 10. [L-thyroxine propylhexedrine in the treatment of obesity. Crossed double blind study].
    González Barranco J; Rull JA; Lozano Castañeda O
    Prensa Med Mex; 1974; 39(5-6):298-9. PubMed ID: 4612507
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of a new anorexic agent in adolescence.
    Bauta HP
    Conn Med; 1974 Sep; 38(9):460-3. PubMed ID: 4606529
    [No Abstract]   [Full Text] [Related]  

  • 12. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of three anorexiants. Clortermine hydrochloride (voranil), fenfluramine hydrochloride (pondimin), and mazindol (sanorex).
    Dykes MH
    JAMA; 1974 Oct; 230(2):270-2. PubMed ID: 4606535
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical evaluation of the anorexic activity and safety of 42-548 in children. Report of a clinical trial.
    Sharma RK; Collipp PJ; Rezvani I; Strimas J; Maddaiah VT; Rezvani E
    Clin Pediatr (Phila); 1973 Mar; 12(3):145-9. PubMed ID: 4573674
    [No Abstract]   [Full Text] [Related]  

  • 15. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study.
    Truant AP; Olon LP; Cobb S
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):726-38. PubMed ID: 4629111
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mazindol, an anorectic of a new series, in the treatment of obesity (author's transl)].
    Dolecek R
    Cas Lek Cesk; 1975 Feb; 114(8):249-54. PubMed ID: 1095197
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 18. [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].
    Gołebiowska M; Chlebna-Sokoł D; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(2):311-4. PubMed ID: 7017826
    [No Abstract]   [Full Text] [Related]  

  • 19. A controlled trial of mazindol (Sanjorex, Teronac) in the management of the obese rheumatic patients.
    Thorpe PC; Isaac PF; Rodgers J
    Curr Ther Res Clin Exp; 1975 Feb; 17(2):149-55. PubMed ID: 803428
    [No Abstract]   [Full Text] [Related]  

  • 20. Double-blind comparison of efficacy, safety, and side effects of Bionamin, phentermine compound, and placebo in the treatment of exogenous obesity.
    Cohen A; De Felice EA; Leb SM; Fuentes JG; Rothwell KG; Truant AP
    Curr Ther Res Clin Exp; 1968 Jul; 10(7):323-34. PubMed ID: 4969672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.